
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. is experiencing a positive outlook due to the continued strong positioning of its lead molecule, cabozantinib, which has shown long-term efficacy data in renal cell carcinoma (RCC) and expanding opportunities in neuroendocrine tumors (NETs) following recent label expansions. The company's development program for zanzalintinib, which has demonstrated statistically significant improvements in overall survival compared to regorafenib, suggests a growing competitive advantage in the metastatic colorectal cancer (mCRC) market. Additionally, the collaboration with Roche for the combination therapy further highlights Exelixis’s strategic potential for future growth in various oncology indications, reinforcing confidence in its prospects.
Bears say
The analysis indicates a significant concern regarding Exelixis, Inc.'s financial outlook due to an anticipated 80% revenue decline following the patent expiration of key products in 2031, which is more severe than the market's expectation of a 68% drop. Additionally, competitive pressures threaten the company’s market share, particularly for its drug cabozantinib in renal cell carcinoma, compounded by uncertainties surrounding unmet market potential in neuroendocrine tumors and hepatocellular carcinoma. Finally, the developmental risks associated with zanzalintinib and the potential for disappointing data updates further exacerbate the concerns regarding Exelixis's future performance.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares